Pneumonia cost-effectiveness of therapy

Jump to: navigation, search

Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Algorithm

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumonia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumonia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumonia cost-effectiveness of therapy

CDC onPneumonia cost-effectiveness of therapy

Pneumonia cost-effectiveness of therapy in the news

Blogs on Pneumonia cost-effectiveness of therapy

Directions to Hospitals Treating Pneumonia

Risk calculators and risk factors for Pneumonia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hamid Qazi, MD, BSc [2], Alejandro Lemor, M.D. [3]

Overview

Linezolid was compared to vancomycin for the treatment of ventilator-associated pneumonia, and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.[1][2] One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated pneumonia from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. [3]

References

  1. Shorr AF, Susla GM, Kollef MH (2004). "Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin". Crit Care Med. 32 (1): 137–43. doi:10.1097/01.CCM.0000104110.74657.25. PMID 14707572.
  2. De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S; et al. (2009). "Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany". Infection. 37 (2): 123–32. doi:10.1007/s15010-008-8046-7. PMID 19277465.
  3. van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ (2004). "Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units". Crit Care Med. 32 (1): 126–30. doi:10.1097/01.CCM.0000104111.61317.4B. PMID 14707570.

Linked-in.jpg